A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Canagliflozin (Primary) ; Metformin; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CANTATA-MSU
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 08 Jan 2018 Results (n=2536) of pooled analysis of NCT01106625, NCT01106677, NCT01137812 and NCT02025907 trials assessing effect of Canagliflozin on health related quality of life and patients' satisfaction published in The Patient - Patient-Centered Outcomes Research
    • 15 Sep 2017 Results of a post-hoc analysis assessing the effect of Canagliflozin on liver function tests and liver fibrosis in patients from four phase III trials (CANTATA-M, CANTATA-MSU, CANTATA-D and CANTATA-MP) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top